| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-04-17 | Labor L+S (Germany) Symbiosis, newly created unit of BioPharm (Germany) | analytical services | collaboration |
Collaboration agreement | ||
| 2012-04-17 | Angel Biotechnology (UK) TransGenRx (USA) | recombinant interferon product | development |
Development agreement | ||
| 2012-04-17 | GSK (UK) Five Prime Therapeutics (USA) | refractory asthma chronic obstructive pulmonary disease (COPD) |
R&D |
Respiratory diseases - Inflammatory diseases - Allergic diseases | R&D agreement | |
| 2012-04-16 | AstraZeneca (UK) Conformetrix (UK) | Conformetrix’s proprietary NMR-based technology | R&D |
R&D agreement | ||
| 2012-04-16 | Conformetrix (UK) AstraZeneca (UK) | Conformetrix’s proprietary NMR-based technology | R&D collaboration |
|||
| 2012-04-12 | Lonza (Switzerland) Agennix (Germany) | talactoferrin | non-small cell lung cancer | development |
Cancer - Oncology | Production agreement |
| 2012-04-12 | AstraZeneca (UK) Drugs for Neglected Diseases initiative (DNDi) | novel drug candidates | Chagas disease, leishmaniasis, sleeping sickness (human African trypanosomiasis) | R&D |
Infectious diseases - Parasitic diseases | R&D agreement |
| 2012-04-12 | Algeta (Norway) Bayer (Germany) | Alpharadin® (radium-223 chloride) | promotion |
Cancer Oncology | Promotion agreement | |
| 2012-04-12 | Seattle Genetics (USA - WA) Ventana Medical Systems (USA), a member of the Roche Group (Switzerland) | molecular companion diagnostic test to evidentify patients who might respond to treatment with Adcetris® (brentuximab vedotin) based on CD30 expression levels in their tissue specimens | CD30-positive cutaneous T-cell lymphoma (CTCL), CD30-positive mature T-cell lymphomas (MTCL) | collaboration |
Cancer - Oncology | Development agreement |
| 2012-04-12 | ImmunoGenes (Switzerland - Hungary) Amgen (USA) | FcRn-overexpressing transgenic mice | R&D |
R&D agreement | ||
| 2012-04-12 | Antitope (UK) Research Corporation Technologies (USA) | toxic protein warhead for the next generation of antibody drug conjugates (ADCs) | Cancer - Oncology | R&D agreement | ||
| 2012-04-11 | Ipsen (France) Photocure (Norway) | Hexvix® (hexaminolevulinate hydrochloride for intravesical solution) | bladder cancer | licensing |
Cancer - Oncology | Milestone |
| 2012-04-10 | Immutep (France) Lonza (Switzerland) | ImmuFact® IMP321 | first line metastatic breast cancer | development |
Cancer - Oncology | Development agreement |
| 2012-04-05 | GSK (UK) Chiome Bioscience (Japan) | monoclonal antibodies generated with Chiome’s proprietary ADLib® system | cancer,autoimmune diseases | development |
Autoimmune diseases - Cancer - Oncology | Development agreement |
| 2012-04-04 | ImmunoGenes (Switzerland - Hungary) Amgen (USA) | FcRn-overexpressing transgenic mice to generate antibodies against “difficult” antigen targets | R&D agreement | |||
| 2012-04-03 | Roche (Switzerland) the French National Agency for Research on AIDS and Viral Hepatitis (ANRS - France) Baylor Research Institute (USA ) Inserm Transfert (France) | therapeutic vaccines | chronic infectious diseases | R&D |
Infectious diseases | R&D agreement |
| 2012-04-02 | PolyTherics (UK) Spirogen (UK) | antibody-drug conjugates (ADCs) | R&D |
Cancer Oncology | R&D agreement | |
| 2012-03-30 | HTG Molecular Diagnostics (USA) Sanofi (France) | biomarkers - molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent | undisclosed | R&D |
undisclosed | R&D agreement |
| 2012-03-29 | Sanofi (France) Aviesan (France) Inserm Transfert (France) Institut Claudius Regaud (France) | various undisclosed cancers | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-03-28 | Merck Serono (Germany) Bioseek (USA) | use of BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and optimization and nomination of candidates for preclinical development at Merck Serono | undisclosed |
R&D |
Multiple therapeutic areas | R&D agreement |
